MAPK3 and neoplasm: The synergistic anti‐tumor activity of curcumin and carboplatin is due to the inhibition of the Akt/IKKα pathway and the enhancement of ERK1/2 activity that inhibits NF‐κB for carboplatin to act as a chemical sensitizer.172